QuantiFERON-TB gold in-tube implementation for latent tuberculosis diagnosis in a public health clinic: A cost-effectiveness analysis

BMC Infectious Diseases

Volumn 12, Issue , 2012, Pages

  Shah, Maunank ^a   Miele, Kathryn ^a   Choi, Howard ^a   DiPietro, Danielle ^c   Martins Evora, Maria ^b   Marsiglia, Vincent ^b   Dorman, Susan ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BALTIMORE CITY HEALTH DEPARTMENT   (United States)

^c TULANE UNIVERSITY   (United States)

Author keywords

Diagnosis; Implementation; Interferon gamma release assay; Latent tuberculosis; Tuberculosis

Indexed keywords

GAMMA INTERFERON; ISONIAZID; RIFAMPICIN;

ALGORITHM; ARTICLE; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC VALUE; DRUG COST; HEALTH CARE PLANNING; HUMAN; INTERFERON GAMMA RELEASE ASSAY; INTERMETHOD COMPARISON; LATENT TUBERCULOSIS; MAJOR CLINICAL STUDY; PATIENT REFERRAL; PUBLIC HEALTH SERVICE; QUALITY ADJUSTED LIFE YEAR; SCREENING TEST; SENSITIVITY ANALYSIS; TUBERCULIN TEST;

COST-BENEFIT ANALYSIS; HUMANS; INTERFERON-GAMMA; LATENT TUBERCULOSIS; MONTE CARLO METHOD; PUBLIC HEALTH;

EID: 84871174527     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-12-360     Document Type: Article

References (34)

1. Advisory Council for the Elimination of Tuberculosis (ACET) Tuberculosis elimination revisited: obstacles, opportunities, and a renewed commitment. MMWR Recomm Rep 1999, 48(RR-9):1-13. Advisory Council for the Elimination of Tuberculosis (ACET).
2. ATS/CDC/IDSA Controlling tuberculosis in the United States. Am J Respir Crit Care Med 2005, 172(9):1169-1227. ATS/CDC/IDSA.
3. ATS/CDC/IDSA Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR Recomm Rep 2000, 49(RR-6):1-51. ATS/CDC/IDSA.
4. Shah M, Dipietro D, Greenbaum A, Ketemepi S, Martins-Evora M, Marsiglia V, Dorman SE. Programmatic Impact of QuantiFERON-TB Gold In-Tube Implementation on Latent Tuberculosis Diagnosis and Treatment in a Public Health Clinic. PLoS One 2012, 7(5):e36551. 10.1371/journal.pone.0036551, 3346719, 22586476.
5. Ozuah PO, Burton W, Lerro KA, Rosenstock J, Mulvihill M. Assessing the validity of tuberculin skin test readings by trained professionals and patients. Chest 1999, 116(1):104-106. 10.1378/chest.116.1.104, 10424511.
6. Diel R, Loddenkemper R, Nienhaus A. Predictive value of interferon-gamma release assays and tuberculin skin testing for predicting progression from latent TB infection to disease state: a meta-analysis. Chest 2012, 142(1):63-75. 10.1378/chest.11-3157, 22490872.
7. Pai M, Kalantri S, Dheda K. New tools and emerging technologies for the diagnosis of tuberculosis: part I. Latent tuberculosis. Expert Rev Mol Diagn 2006, 6(3):413-422. 10.1586/14737159.6.3.413, 16706743.
8. Pai M, Zwerling A, Menzies D. Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med 2008, 149(3):177-184. 2951987, 18593687.
9. Mazurek GH, Jereb J, Vernon A, LoBue P, Goldberg S, Castro K. Updated guidelines for using Interferon Gamma Release Assays to detect Mycobacterium tuberculosis infection - United States, 2010. MMWR Recomm Rep 2010, 59(RR-5):1-25.
10. Rangaka MX, Wilkinson KA, Glynn JR, Ling D, Menzies D, Mwansa-Kambafwile J, Fielding K, Wilkinson RJ, Pai M. Predictive value of interferon-gamma release assays for incident active tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis 2012, 12(1):45-55. 10.1016/S1473-3099(11)70210-9, 21846592.
11. Kunimoto D, Der E, Beckon A, Thomas L, Egedahl M, Beatch A, Williams G, Tyrrell G, Ahmed R, Brown N, et al. Use of the QuantiFERON-TB Gold test to confirm latent tuberculosis infection in a Canadian tuberculosis clinic. Int J Tuberc Lung Dis 2009, 13(6):726-730.
12. Horsburgh CR. Priorities for the treatment of latent tuberculosis infection in the United States. N Engl J Med 2004, 350(20):2060-2067. 10.1056/NEJMsa031667, 15141044.
13. Pareek M, Watson JP, Ormerod LP, Kon OM, Woltmann G, White PJ, Abubakar I, Lalvani A. Screening of immigrants in the UK for imported latent tuberculosis: a multicentre cohort study and cost-effectiveness analysis. Lancet Infect Dis 2011, 11(6):435-444. 10.1016/S1473-3099(11)70069-X, 3108102, 21514236.
14. Menzies D, Pai M, Comstock G. Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research. Ann Intern Med 2007, 146(5):340-354.
15. Page KR, Sifakis F, Montes de Oca R, Cronin WA, Doherty MC, Federline L, Bur S, Walsh T, Karney W, Milman J, et al. Improved adherence and less toxicity with rifampin vs isoniazid for treatment of latent tuberculosis: a retrospective study. Arch Intern Med 2006, 166(17):1863-1870. 10.1001/archinte.166.17.1863, 17000943.
16. Lardizabal A, Passannante M, Kojakali F, Hayden C, Reichman LB. Enhancement of treatment completion for latent tuberculosis infection with 4 months of rifampin. Chest 2006, 130(6):1712-1717. 10.1378/chest.130.6.1712, 17166986.
17. Pooran A, Booth H, Miller RF, Scott G, Badri M, Huggett JF, Rook G, Zumla A, Dheda K. Different screening strategies (single or dual) for the diagnosis of suspected latent tuberculosis: a cost effectiveness analysis. BMC Pulm Med 2010, 10:7. 10.1186/1471-2466-10-7, 2837635, 20170555.
18. Kunst H, Khan KS. Age-related risk of hepatotoxicity in the treatment of latent tuberculosis infection: a systematic review. Int J Tuberc Lung Dis 2010, 14(11):1374-1381.
19. Ziakas PD, Mylonakis E. 4 months of rifampin compared with 9 months of isoniazid for the management of latent tuberculosis infection: a meta-analysis and cost-effectiveness study that focuses on compliance and liver toxicity. Clin Infect Dis 2009, 49(12):1883-1889. 10.1086/647944, 19911936.
20. Holland DP, Sanders GD, Hamilton CD, Stout JE. Costs and cost-effectiveness of four treatment regimens for latent tuberculosis infection. Am J Respir Crit Care Med 2009, 179(11):1055-1060. 10.1164/rccm.200901-0153OC, 2689913, 19299495.
21. de Perio MA, Tsevat J, Roselle GA, Kralovic SM, Eckman MH. Cost-effectiveness of interferon gamma release assays vs tuberculin skin tests in health care workers. Arch Intern Med 2009, 169(2):179-187. 10.1001/archinternmed.2008.524, 19171815.
22. WHO Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. International Union Against Tuberculosis Committee on Prophylaxis. Bull World Health Organ 1982, 60(4):555-564. 2536088, 6754120, WHO.
23. Brown RE, Miller B, Taylor WR, Palmer C, Bosco L, Nicola RM, Zelinger J, Simpson K. Health-care expenditures for tuberculosis in the United States. Arch Intern Med 1995, 155(15):1595-1600. 10.1001/archinte.1995.00430150057006, 7618981.
24. Maryland TB. Statistics, Department of Health and Mental Hygiene http://ideha.dhmh.maryland.gov/CTBCP/statistics.aspx.
25. Harstad I, Winje BA, Heldal E, Oftung F, Jacobsen GW. Predictive values of QuantiFERON-TB Gold testing in screening for tuberculosis disease in asylum seekers. Int J Tuberc Lung Dis 2010, 14(9):1209-1211.
26. Diel R, Loddenkemper R, Niemann S, Meywald-Walter K, Nienhaus A. Negative and positive predictive value of a whole-blood interferon-gamma release assay for developing active tuberculosis: an update. Am J Respir Crit Care Med 2011, 183(1):88-95. 10.1164/rccm.201006-0974OC, 20802162.
27. Diel R, Loddenkemper R, Meywald-Walter K, Niemann S, Nienhaus A. Predictive value of a whole blood IFN-gamma assay for the development of active tuberculosis disease after recent infection with Mycobacterium tuberculosis. Am J Respir Crit Care Med 2008, 177(10):1164-1170. 10.1164/rccm.200711-1613OC, 18276940.
28. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA 1996, 276(15):1253-1258. 10.1001/jama.1996.03540150055031, 8849754.
29. Life Expectancy Tables http://www.cdc.gov/nchs/fastats/lifexpec.htm.
30. Reported Tuberculosis in the United States 2009, http://www.cdc.gov/tb/statistics/reports/2010/pdf/report2010.pdf.
31. Maryland TB Guidelines for Prevention and Treatment of Tuberculosis http://ideha.dhmh.maryland.gov/OIDPCS/CTBCP/CTBCPDocuments/tbguidelines.pdf.
32. Owens DK. Interpretation of cost-effectiveness analyses. J Gen Intern Med 1998, 13(10):716-717. 10.1046/j.1525-1497.1998.00211.x, 1497852, 9798822.
33. Nienhaus A, Schablon A, Costa JT, Diel R. Systematic review of cost and cost-effectiveness of different TB-screening strategies. BMC Health Serv Res 2011, 11:247. 10.1186/1472-6963-11-247, 3196701, 21961888.
34. Dewan PK, Grinsdale J, Liska S, Wong E, Fallstad R, Kawamura LM. Feasibility, acceptability, and cost of tuberculosis testing by whole-blood interferon-gamma assay. BMC Infect Dis 2006, 6:47. 10.1186/1471-2334-6-47, 1434750, 16539718.